Key result
Patients with acute decompensated heart failure and mildly reduced ejection fraction had a higher risk of cardiovascular death and heart failure rehospitalization compared to those with preserved ejection fraction.
Why the study?
Little research has investigated ischemic outcomes related to left ventricular ejection fraction in acute decompensated heart failure.
Does the HFmrEF phenotype alter the risk of ischemic outcomes and mortality compared to HFrEF and HFpEF in patients with acute decompensated heart failure?
Cohort (n=12,852)
Yes
Does the HFmrEF phenotype alter the risk of ischemic outcomes and mortality compared to HFrEF and HFpEF in patients with acute decompensated heart failure?
In patients with acute decompensated heart failure, the HFmrEF phenotype is associated with a distinct comorbidity profile and a higher crude rate of acute myocardial infarction compared to HFrEF and HFpEF.
Answers are grounded in this paper and cite their sources.
HFmrEF signals elevated CV death and rehospitalization risk in acute decompensated HF; leaves open whether phenotype-specific interventions improve outcomes.
BACKGROUND: Little research has been done on ischemic outcomes related to left ventricular ejection fraction (EF) in acute decompensated heart failure (ADHF). METHODS: A retrospective cohort study was conducted between 2001 and 2021 using the Chang Gung Research Database. ADHF Patients discharged from hospitals between January 1, 2005, and December 31, 2019. Cardiovascular (CV) mortality and heart failure (HF) rehospitalization are the primary outcome components, along with all-cause mortality, acute myocardial infarction (AMI) and stroke. RESULTS: A total of 12,852 ADHF patients were identified, of whom 2,222 (17.3%) had HFmrEF, the mean (SD) age was 68.5 (14.6) years, and 1,327 (59.7%) were males. In comparison with HFrEF and HFpEF patients, HFmrEF patients had a significant phenotype comorbid with diabetes, dyslipidemia, and ischemic heart disease. Patients with HFmrEF were more likely to experience renal failure, dialysis, and replacement. Both HFmrEF and HFrEF had similar rates of cardioversion and coronary interventions. There was an intermediate clinical outcome between HFpEF and HFrEF, but HFmrEF had the highest rate of AMI (HFpEF, 9.3%; HFmrEF, 13.6%; HFrEF, 9.9%). The AMI rates in HFmrEF were higher than those in HFpEF (AHR, 1.15; 95% Confidence Interval, 0.99 to 1.32) but not in HFrEF (AHR, 0.99; 95% Confidence Interval, 0.87 to 1.13). CONCLUSION: Acute decompression in patients with HFmrEF increases the risk of myocardial infarction. The relationship between HFmrEF and ischemic cardiomyopathy, as well as optimal anti-ischemic treatment, requires further research on a large scale.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2023) conducted a cohort in Acute decompensated heart failure (n=12,852). Heart failure with mildly reduced ejection fraction (HFmrEF) vs. Heart failure with preserved ejection fraction (HFpEF) was evaluated on Cardiovascular death and heart failure rehospitalization (AHR 1.11, 95% CI 1.04-1.18, p=0.002). Patients with acute decompensated heart failure and mildly reduced ejection fraction had a higher risk of cardiovascular death and heart failure rehospitalization compared to those with preserved ejection fraction.
Synapse has enriched 10 related papers. Consider them for comparative context: